Bendamustine

Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States

Retrieved on: 
Wednesday, April 26, 2023
CLL, NHL, Indolent, FDA, Apotex, Patient, Chronic lymphocytic leukemia, Generic drug, Bendamustine

WESTON, Fla., April 26, 2023 /PRNewswire/ - Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.

Key Points: 
  • WESTON, Fla., April 26, 2023 /PRNewswire/ - Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.
  • Bendamustine hydrochloride injection is an alkylating drug approved by the FDA for treatment of patients with Chronic lymphocytic leukemia (CLL) and Indolent B-cell non-Hodgkin lymphoma (NHL).
  • Apotex's Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL), New Drug Application No.
  • "We're excited to launch this injection product, which provides an affordable, high-quality option for Americans undergoing cancer treatment," said Peter Hardwick, President, Apotex Corp.

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Monday, March 13, 2023
Federal Deposit Insurance Corporation, Regulation of tobacco by the U.S. Food and Drug Administration, Orange Book, Internet, Tariff, Chase Bank, Platinum, Bendamustine, Food and Drug Administration, IQVIA, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, ALK, U.S. Department of Justice Office of Legislative Affairs, Silicon, Total, Eagle, Bronchopneumonia, Acquisition, Patient, Pembrolizumab, Accord, Apnea, Food, JPMorgan Chase, Community-acquired pneumonia, Silicon Valley Bank, Growth, Justice, Pemetrexed, FDA, Lung cancer, Self storage, Beauty salon, Music, Pharmaceutical industry, Vaccine, Cryptocurrency, Video game

During the fourth quarter of 2022, the Company reached the contractual limit for royalties paid to development partner on worldwide bendamustine profits.

Key Points: 
  • During the fourth quarter of 2022, the Company reached the contractual limit for royalties paid to development partner on worldwide bendamustine profits.
  • “2022 was an outstanding year for Eagle, as we tripled our adjusted non-GAAP net income per diluted share over 2021.
  • Q4 2022 RYANODEX® net product sales were $7.2 million, compared to $6.1 million in the fourth quarter of 2021.
  • Q4 2022 BELRAPZO net product sales were $11.0 million, compared to $5.5 million in the fourth quarter of 2021.

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Bendamustine, JW, Therapy, Lymphatic system, ORR, HKEX, National Medical Products Administration, NMPA, MCL, Bristol Myers Squibb, Society, Patient, Follicular lymphoma, Degenerative disease, B-cell lymphoma, CRR, Safety, Incidence, Efficacy, CRS, Juno Therapeutics, Hope, ASH, Vaccine, Pharmaceutical industry

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection) in Chinese adults with relapsed/refractory follicular lymphoma (r/r FL) and relapsed/refractory mantle cell lymphoma (r/r MCL) at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection) in Chinese adults with relapsed/refractory follicular lymphoma (r/r FL) and relapsed/refractory mantle cell lymphoma (r/r MCL) at the 64th American Society of Hematology (ASH) Annual Meeting.
  • Eligible patients were randomized to received relma-cel at the dose level of 100106 or 150106 CAR+ T cells, following lymphodepletion chemotherapy.
  • Updated safety and efficacy data with a longer follow-up will be presented.
  • JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Retrieved on: 
Wednesday, December 7, 2022
CLL, Heart, Food, Rash, Teva, Cough, NHL, Patient, Diarrhea, Chronic lymphocytic leukemia, Research, Food and Drug Administration, Nausea, Aplastic anemia, Headache, United States National Library of Medicine, Fatigue, FDA, Vomiting, Injection, Breathe Me, US Foods, MedlinePlus, Pharmacist, Anaphylaxis, Growth, Constipation, AP, Safety, Purging disorder, Accord, National library, Infection, Tumor lysis syndrome, Rituximab, Intas Biopharmaceuticals, MEDLINE, Pharmaceutical industry, Fever, Bendamustine

DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs. Accord's product is AP rated to Teva's Treanda® and is being offered in both 25-mg and 100-mg vials.

Key Points: 
  • DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Bendamustine Lyo.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.
  • Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do.

Systemic Lupus Erythematosus Pipeline Market Analysis Report 2022: Comprehensive Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Other Health, B cell, II, Chronic lymphocytic leukemia, Degenerative disease, News, Patient, LANCL2, SLE, Obinutuzumab, Mergers and acquisitions, CD20, Clinical trial, Lupus, Novartis, Ianalumab, RA, Roche, III, Technology, Idiopathic disease, Pathology, Rheumatoid arthritis, NDA, Therapy, Discovery, Immune system, Acquisition, Idiopathic pulmonary fibrosis, BAFF, Oil, Generic drug, Pharmaceutical industry, Vaccine, EU, Bendamustine

This "Systemic Lupus Erythematosus- Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape.

Key Points: 
  • This "Systemic Lupus Erythematosus- Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape.
  • "Systemic Lupus Erythematosus- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Systemic Lupus Erythematosus pipeline landscape is provided which includes the disease overview and Systemic Lupus Erythematosus treatment guidelines.
  • The assessment part of the report embraces, in depth Systemic Lupus Erythematosus commercial assessment and clinical assessment of the pipeline products under development.

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

Retrieved on: 
Tuesday, April 19, 2022
Anonymous Online Speakers v. United States District Court for the District of Nevada, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Research, CNS, GLOBE, Supreme court, Fresenius, Review, Eagle, Ciba-Geigy Canada Ltd v Apotex Inc, Forward-looking statement, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, FDA, Drug development, United States Court of Appeals for the Federal Circuit, Mylan, United States courts of appeals, Annual report, Compliance, Private Securities Litigation Reform Act, Justice, Company, Hospira, LLC, District, Orange, Intellectual property, Failure, Nasdaq, U.S. Department of Justice Office of Legislative Affairs, SEC, Law of the United Kingdom, Patent, Apotex, Phrase, Biotechnology, Lesbian flag, Orange Book, District court, Pharmaceutical industry, Bendamustine

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has reached a settlement agreement with Hospira, Inc (Hospira).

Key Points: 
  • WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has reached a settlement agreement with Hospira, Inc (Hospira).
  • Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (NDA) referencing BENDEKA.
  • The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.
  • The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Global Bendamustine (CAS 16506-27-7) Market Report 2021: Market Trends and Development, Major Players & Main Downstream Sectors - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Chemicals, Plastics, Manufacturing, Industry, CAS, Renewable energy, Explosive, Clothing, Fine chemical, Bendamustine

The "Bendamustine (CAS 16506-27-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bendamustine (CAS 16506-27-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Bendamustine.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Bendamustine market trends and forecast, distinguish Bendamustine manufacturers and suppliers.

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Retrieved on: 
Tuesday, April 21, 2020
RTT, Drugs, Breakthrough therapy, Genentech, Chemical compounds, Cancer treatments, Hoffmann-La Roche, Obinutuzumab, Rituximab, Ibrutinib, Chronic lymphocytic leukemia, Bendamustine

For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR).

Key Points: 
  • For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR).
  • When administering IMBRUVICA in combination with rituximab or obinutuzumab, consider administering IMBRUVICA prior to rituximab or obinutuzumab when given on the same day.
  • Monitor blood pressure in patients treated with IMBRUVICA and initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA as appropriate.
  • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation

Retrieved on: 
Monday, March 30, 2020
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Bendamustine, Benzimidazoles, Organochlorides, RTT, Pharmaceutical industry in China, Health, Chemistry

Eagle Pharmaceuticals, Inc. (Eagle or the Company) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (SymBio) has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion (RI), a liquid bendamustine injection with a 10-minute administration time, in Japan.

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Eagle or the Company) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (SymBio) has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion (RI), a liquid bendamustine injection with a 10-minute administration time, in Japan.
  • As previously disclosed, SymBio filed an NDA for its TREAKISYM ready-to-dilute (RTD) product in October 2019.
  • In September 2017, Eagle licensed to SymBio intellectual property necessary to develop, market and sell RTD and RI formulations of TREAKISYM in Japan.
  • As part of the agreement, SymBio assumed responsibility for securing regulatory approval of the TREAKISYM RTD and RI injection products using the licensed technology in Japan.

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Retrieved on: 
Sunday, December 8, 2019
Chemical compounds, RTT, Drugs, Cancer treatments, Genentech, Breakthrough therapy, Specialty drugs, Chronic lymphocytic leukemia, Bendamustine, Rituximab, Venetoclax, Chemotherapy regimen

"The sustained efficacy and manageable safety profile observed in the study further supportthe clinical benefits of fixed treatment in patients with relapsed or refractory chronic lymphocytic leukemia."

Key Points: 
  • "The sustained efficacy and manageable safety profile observed in the study further supportthe clinical benefits of fixed treatment in patients with relapsed or refractory chronic lymphocytic leukemia."
  • The trial was designed to evaluate the efficacy and safety of venetoclax in combination with rituximab (n=194) compared with bendamustine in combination with rituximab (n=195).
  • The median age of patients in the trial was 65 years (range: 22 to 85).3
    The primary efficacy endpoint was INV-assessed PFS.
  • Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL).